Underdiagnosing women is not an option.
High-sensitivity cardiac troponin (hs-cTn) assays must establish sex-specific 99th percentile upper reference limits (URLs) because healthy women have inherently lower baseline troponin concentrations than healthy men. Using a single, unisex cutoff would systematically miss myocardial injury in female patients, leading to underdiagnosis of acute myocardial infarction and non-ST-elevation myocardial infarction (NSTEMI). For assay developers, sex-specific URLs are not a refinement—they are a fundamental requirement for achieving true diagnostic accuracy and meeting international analytical performance standards.
The biological reality of lower cardiac troponin levels in women makes a unified 99th percentile cutoff clinically dangerous. Sex‑specific thresholds transform a high-sensitivity assay from a tool that merely detects troponin into one that delivers equal diagnostic sensitivity for every patient, regardless of sex.
The Biological Foundation: Why Men and Women Differ
Baseline Troponin Concentrations Are Not Equal
Healthy women consistently express lower circulating levels of cardiac troponin (cTn) than healthy men. This difference is well‑documented across populations and persists even when using highly sensitive detection methods. It is not a trivial variation but a fundamental physiological distinction that directly influences where a pathological “elevation” is defined.
The 99th Percentile URL Is the Diagnostic Gatekeeper
Clinical guidelines define the 99th percentile URL as the statistically derived threshold obtained from a healthy reference population. A troponin value above this URL signals myocardial injury. The 99th percentile serves as the diagnostic cutoff for acute myocardial infarction, making its accuracy the single most influential factor in early rule‑in and rule‑out protocols.
The Clinical Imperative: Avoiding Systematic Underdiagnosis
The Hidden Cost of a One‑Size‑Fits‑All Cutoff
When developers apply a single 99th percentile URL derived from a mixed‑sex population, the cutoff is biased toward the higher male baseline. As a result, many women with true, evolving myocardial necrosis will have troponin values that fall below this unisex threshold, yet are clearly abnormal for their own physiology. This leads to missed diagnoses, delayed treatment, and poorer outcomes—particularly in NSTEMI, where subtle elevations are the primary diagnostic signal.
International Guidelines Demand Sex‑Specific Thresholds
Major cardiology societies (ESC, ACC, AHA, WHF) explicitly recommend establishing sex‑specific 99th percentile URLs for hs‑cTn assays. These recommendations exist because clinical evidence shows that a sex‑blind approach compromises diagnostic sensitivity in women. Developers who ignore this guidance produce assays that are not aligned with best practice and may face barriers to clinical adoption.
The Analytical Development Challenge
High‑Sensitivity Classification Depends on Sex‑Specific Performance
To qualify as a high‑sensitivity assay, a test must measure cardiac troponin concentrations at or above the limit of detection in at least 50% of healthy women and at least 50% of healthy men—assessed individually using sex‑specific URLs. If an assay cannot detect troponin in more than half of the female reference cohort because the detection system is not sensitive enough at their lower baseline, it fails the high‑sensitivity criteria entirely.
Raw Material Choices Are the Foundation of Sensitivity
Meeting the 50% detection requirement and achieving ≤10% coefficient of variation (CV) at the lower female 99th percentile URL places extreme demands on raw materials. Developers must select high‑affinity capture and detection antibodies (e.g., monoclonal anti‑cTnI or anti‑cTnT antibodies) that produce an intense signal at picogram levels. They also need optimized blockers, stable calibrators, and low‑background reagent formulations. The female cutoff is the most demanding benchmark; without it, the assay’s sensitivity is not truly validated.
Understanding the Trade‑offs
Increased Complexity in Reference Range Studies
Establishing sex‑specific URLs requires recruiting larger, well‑characterized healthy cohorts and applying statistically rigorous CLSI protocols for each sex separately. This adds time, cost, and logistical burden to reference range studies. Developers must invest in appropriate population sampling and robust statistical analysis to derive cutoffs that are both accurate and defensible.
Potential for Initial Clinical Confusion
Two cutoffs can introduce interpretive ambiguity if laboratory reports and clinical decision support systems are not clearly designed. However, this challenge is surmountable. Automated flags in laboratory information systems and clear report annotations quickly educate clinicians, and the diagnostic gain far outweighs the minor inconvenience of managing two numbers.
Precision Demands Intensify at the Female Cutoff
Because the female 99th percentile URL is numerically lower, the assay must maintain excellent analytical imprecision (ideally ≤10% CV) at an even lower concentration. This pushes the limits of antibody affinity, signal‑to‑noise ratio, and immunoassay optimization. Low‑level noise that would be acceptable near a higher male cutoff can cause misclassification at the female threshold, making raw material performance non‑negotiable.
Making the Right Choice for Your Assay
Every hs‑cTn developer faces a clear set of strategic decisions. Your approach to sex‑specific URLs must be proactive, not retrofitted.
- If your primary focus is regulatory compliance and high‑sensitivity classification: Embed sex‑specific cutoff validation into your development plan early. Use separate healthy male and female cohorts and document detection rates and CV performance for each sex to meet guideline criteria.
- If your primary focus is maximizing clinical sensitivity in emergency settings: Prioritize antibody pairs and detection chemistries that generate reliable signal at the lower female troponin range. Confirm that your assay can measure cTn in >50% of healthy women, because this is the true proving ground for sensitivity.
- If your primary focus is ensuring seamless clinical adoption: Invest in clear software integration and educational materials that make sex‑specific reporting intuitive for physicians. The diagnostic superiority of sex‑specific cutoffs only translates into better patient care when the information is acted upon without hesitation.
Designing an hs‑cTn assay without sex‑specific 99th percentile URLs is like calibrating a scale that systematically ignores lighter weights—it simply does not measure what it claims to measure, and the people it overlooks are those who need it most.
Summary Table:
| Aspect | Single Unisex Cutoff | Sex-Specific 99th Percentile URLs |
|---|---|---|
| Female Sensitivity | Risk of underdiagnosis & missed NSTEMI | Accurate detection for female baseline |
| Regulatory Compliance | Non-compliant with ESC/ACC/AHA guidelines | Meets global clinical & analytical standards |
| Raw Material Demands | Lower sensitivity requirement | Requires ultra-high affinity antibodies & ≤10% CV |
Developing high-sensitivity cardiac troponin assays that meet demanding sex-specific performance standards? CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Partner with us to source high-affinity antibodies and optimize your assay sensitivity. Contact us today to advance your development pipeline!